{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023202","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2026-05-14T21:27:11+00:00","discovered_at":"2026-05-14T21:28:00.294463+00:00","generated_at":"2026-05-14T21:28:06.102147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM","bullets":["Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.","Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.","Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.","R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.","Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023202","json":"https://secwatch.observer/filing/0001493152-26-023202.json","markdown":"https://secwatch.observer/filing/0001493152-26-023202.md","text":"https://secwatch.observer/filing/0001493152-26-023202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023202/0001493152-26-023202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023202/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:28:06.102147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"522f309cb6da5c3a5cd61fdd2e7d8c36f627d723","claim":"Glucotrack, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of.","evidence_excerpt":"Net Loss: Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023202/0001493152-26-023202-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}